#CTXR hashtag - Bluesky

Citius Pharmaceuticals Unveils 2025 Financial Results and Strategic 2026 Goals Citius Pharmaceuticals Inc. reports significant business developments post-FY 2025, including the launch of immunotherapy LYMPHIR for CTCL patients and upcoming market strategies.

3 months ago

Citius Pharmaceuticals Unveils 2025 Financial Results and Strategic 2026 Goals #USA #CTXR #Cranford #LYMPHIR #Citius_Oncology

0 0 0 0

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025. Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR. With the U.S. commercial launch of LYMPHIR now...

3 months ago

#CTOR #CTXR Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025. CRANFORD, N.J., Dec. 23, 2025/ PRNewswire/-- Citius Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year...

3 months ago

#CTOR #CTXR Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTOR/citius-pharmac...

0 0 0 0

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim Citius Oncology (Nasdaq: CTOR) announced on December 4, 2025 an exclusive distribution agreement with Er-Kim to commercialize LYMPHIR (denileukin diftitox-cxdl) in Turkey and Gulf Cooperation Council countries: Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates.The partnership expands LYMPHIR international availability to 19 markets outside the U.S., using Named Patient Programs where permitted by local law. LYMPHIR is an FDA-approved IL-2 receptor-directed cytotoxin for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. Under the agreement, Er-Kim will handle sales, marketing and reimbursement while Citius Oncology supplies finished product and provides support.

4 months ago

#CTOR #CTXR Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) CRANFORD, N.J., Dec. 1, 2025/ PRNewswire/-- Citius Oncology, Inc., the oncology-focused subsidiary of Citius Pharmaceuticals, Inc., today announced the commercial launch of LYMPHIR™. LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I– III...

4 months ago

#CTOR #CTXR Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Trade Alerts, Wednesday November 26, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Wed Nov 26th - #PW #BQ #WOOF #VRCA #TSSI #ONEW #MESO #KALA #DEFT #CTXR #AMBR - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch. CRANFORD, N.J., Nov. 21, 2025/ PRNewswire/-- Citius Oncology, Inc., the oncology-focused subsidiary of Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company...

4 months ago

#CTOR #CTXR Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals (Nasdaq: CTXR) announced a registered direct offering to sell 3,973,510 shares (or pre-funded warrants) and accompanying common warrants to buy up to 3,973,510 shares at a purchase price of $1.51 per share, generating approximately $6.0 million in gross proceeds before fees. The common warrants carry a $1.40 exercise price, are exercisable immediately, and expire five years from the initial exercise date. Closing is expected on or about October 21, 2025, subject to customary conditions, with H.C. Wainwright acting as exclusive placement agent. Net proceeds are planned to support the commercial launch of LYMPHIR, product development, milestone and regulatory payments, and general corporate purposes.

5 months ago

#CTXR Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/CTXR/citius-pharmac...

0 0 0 0

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch Citius Oncology (Nasdaq: CTOR) signed a U.S. distribution services agreement with McKesson (NYSE: MCK) to serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl).LYMPHIR is FDA approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. The McKesson agreement completes Citius Oncology's core U.S. distribution network with all three largest pharmaceutical wholesalers, supporting the planned commercial launch in Q4 2025. The company also cites inventory readiness, permanent J-code J9161, NCCN guideline inclusion, and provider and patient education resources as part of its commercialization preparations.

5 months ago

#CTOR #CTXR #MCK Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ Citius Oncology (Nasdaq: CTOR) finalized an exclusive Master Service Agreement with EVERSANA to support the planned U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl) in Q4 2025. EVERSANA will provide an integrated suite of pre- and post-launch services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. LYMPHIR was approved by the U.S. FDA in August 2024 for relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. The agreement is exclusive and intended to scale launch operations and market access for LYMPHIR in the United States.

5 months ago

#CTOR #CTXR Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch Citius Oncology (NASDAQ:CTOR) has announced the deployment of a proprietary AI platform to enhance its commercial team's performance ahead of the anticipated LYMPHIR™ launch for cutaneous T-cell lymphoma (CTCL) treatment. The platform leverages advanced data analytics and machine learning to identify potential LYMPHIR candidates and optimize healthcare provider engagement.The AI system analyzes treatment patterns and diagnosis data to support targeted prescriber outreach. It features a continuous learning model that integrates real-world U.S. claims data and marketing performance analytics to deliver predictive insights and enable personalized customer engagement across digital and in-person channels.

7 months ago

#CTOR #CTXR Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Oncology Launches $9 Million Public Offering to Fund LYMPHIR Commercialization Citius Oncology has announced a public offering priced at $9 million to support the commercialization of its oncology therapy LYMPHIR. This article covers the details.

8 months ago

Citius Oncology Launches $9 Million Public Offering to Fund LYMPHIR Commercialization #United_States #CTXR #Cranford #Citius_Oncology #Lympir

0 0 0 0

Citius Oncology Announces Pricing of $9.0 Million Public Offering Citius Oncology (NASDAQ:CTOR) has announced the pricing of a public offering to raise $9.0 million through the sale of 6,818,182 shares of common stock and warrants at $1.32 per share. The warrants will have the same exercise price, be immediately exercisable, and expire in five years.The company plans to use the proceeds primarily for the commercialization of LYMPHIR, including milestone and royalty payments, as well as working capital. The offering, managed by Maxim Group LLC as sole placement agent, is expected to close around July 17, 2025.

8 months ago

#CTOR #CTXR Citius Oncology Announces Pricing of $9.0 Million Public Offering

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Oncology Secures Major Distribution Deal for New FDA-Approved Lymphoma Treatment LYMPHIR Citius Oncology teams with Cencora to enhance distribution network for LYMPHIR, its FDA-approved immunotherapy for CTCL. Learn about market expansion strategy.

8 months ago

#CTOR #CTXR Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Pharmaceuticals Meets Nasdaq's Minimum Bid Price Requirement and Maintains Listing Citius Pharmaceuticals has successfully met the Nasdaq minimum bid price requirement, maintaining its listing after a period of compliance. The company continues to focus on critical care product development.

8 months ago

Citius Pharmaceuticals Meets Nasdaq's Minimum Bid Price Requirement and Maintains Listing #United_States #NASDAQ #CTXR #Citius_Pharmaceuticals #Cranford,_New_Jersey

0 0 0 0

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 Citius Oncology (NASDAQ: CTOR) is preparing for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for treating adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), scheduled for the second half of 2025. The company has completed key launch preparations including commercial-scale manufacturing with 60-month shelf life inventory sufficient for 12-18 months post-launch. Distribution agreements with global logistics partners are being finalized to ensure broad U.S. access. The company has garnered significant interest from the medical community, with 70 institutional oncology centers already registered. LYMPHIR has secured NCCN guideline inclusion and a permanent J-code, positioning it well for reimbursement. The recent capital raise by parent company Citius Pharma (NASDAQ: CTXR) supports the launch, while strategic partnership discussions are ongoing to expand market reach.

9 months ago

#CTOR #CTXR Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

www.stocktitan.net/news/CTOR/citius-oncolog...

0 0 0 0

Citius Pharmaceuticals Completes $15.8 Million Registered Direct Offering for Oncology Product Development Citius Pharmaceuticals has successfully closed a registered direct offering, raising $15.8 million, to support the launch of its oncology treatment LYMPHIR™ and other pharmaceuticals.

9 months ago

Citius Pharmaceuticals Completes $15.8 Million Registered Direct Offering for Oncology Product Development #United_States #CTXR #Cranford #Citius_Pharmaceuticals #LYMPHIR

0 0 0 0

Citius Pharmaceuticals Secures $15.8M Strategic Financing: LYMPHIR Commercial Launch Gets Green Light Just announced: $6M upfront plus $9.8M in warrants to fund LYMPHIR commercial rollout. See detailed terms of the strategic financing and launch timeline.

9 months ago

#CTXR Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/CTXR/citius-pharmac...

0 0 0 0

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health Citius Oncology (CTOR), a subsidiary of Citius Pharmaceuticals (CTXR), has secured a distribution services agreement with Cardinal Health (CAH) for LYMPHIR, their FDA-approved immunotherapy treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults. The partnership positions Cardinal Health as an authorized distributor of record, leveraging their established pharmaceutical distribution network to facilitate LYMPHIR's upcoming U.S. commercial launch. This strategic agreement aims to ensure efficient and reliable delivery of LYMPHIR to healthcare providers and patients, marking a significant milestone in Citius Oncology's launch preparation strategy.

9 months ago

#CTXR #CTOR #CAH Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

www.stocktitan.net/news/CTXR/citius-oncolog...

0 0 0 0

Citius Pharmaceuticals Reports Strong Financial Progress with FDA Approval on the Horizon Citius Pharmaceuticals shares financial updates and strategic plans, emphasizing their push towards the launch of LYMPHIR and enhanced market position.

10 months ago

Citius Pharmaceuticals Reports Strong Financial Progress with FDA Approval on the Horizon #United_States #CTXR #Cranford #Citius_Pharmaceuticals #LYMPHIR

0 0 0 0

Citius Pharmaceuticals Reports Critical Cash Position, Advances FDA-Approved LYMPHIR Launch Strategy Latest earnings reveal $26K cash position, strategic funding needs for LYMPHIR commercialization. See updated Mino-Lok FDA submission timeline and partnership plans.

10 months ago

#CTXR Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTXR/citius-pharmac...

0 0 0 0

Citius Secures Strategic $2M Funding to Accelerate LYMPHIR Launch - Key Details Revealed Citius raises $2M through direct stock offering at $1.15/share to fund LYMPHIR commercial launch. Strategic financing details and growth implications inside.

1 year ago

#CTXR Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

www.stocktitan.net/news/CTXR/citius-pharmac...

0 0 0 0

Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M Citius reports wider Q1 losses while preparing for LYMPHIR's H1 2025 launch. Secured J-code J9161, raised $6.5M, but cash position remains tight at $1.1M.

1 year ago

#CTXR #CTOR Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTXR/citius-pharmac...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bullish crossover of moving average convergence divergence signal, Mon Feb 10th - #UDMY #PAYS #NRC #MNRO #APTO #BLBD #CTXR #DMLP #FFIE #GSM #HROW #VANI #SSSS #OCFC #KOSS #IKNA #UP #LICY #UP #KOP #HLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients LYMPHIR receives permanent J-code (J9161) from Medicare, streamlining reimbursement for cutaneous T-cell lymphoma treatment. Code effective April 2025, expanding patient access.

1 year ago

#CTXR #CTOR Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

www.stocktitan.net/news/CTXR/citius-pharmac...

0 0 0 0

Citius Pharmaceuticals Secures $3 Million in Direct Offering Under Nasdaq Regulations Citius Pharmaceuticals has announced a pivotal $3 million registered direct offering, expanding its financial capabilities for product development and growth.

1 year ago

Citius Pharmaceuticals Secures $3 Million in Direct Offering Under Nasdaq Regulations #FDA_Approval #CTXR #Citius_Pharmaceuticals

0 0 0 0